Drug intelligence / Profile preview

18F-NOTA-CRT

Development stage: Preclinical
Lead developer: Sun Yat-sen University Cancer Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

18F-NOTA-CRT is a PET/CT imaging probe designed to target Transferrin Receptor 1 (TfR 1), which is frequently overexpressed in glioblastoma (GBM). The probe consists of the CRTIGPSVC (CRT) peptide, which has a high affinity for GBM tissues, conjugated to the chelator NOTA and labeled with the radioisotope fluorine-18 (18F). It is intended for the precise detection of intracranial tumor burden and to assist in identifying patients with TfR 1 overexpression who might benefit from targeted therapies or fluorescence-guided surgery using related probes like Cy5-CRT.

Other names: 18F-NOTA-CRTIGPSVC[18F]NOTA-CRT

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on 18F-NOTA-CRT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-NOTA-CRT.

Explore the full profile